000274183 001__ 274183
000274183 005__ 20240229154927.0
000274183 0247_ $$2doi$$a10.1093/cid/ciad131
000274183 0247_ $$2pmid$$apmid:36883586
000274183 0247_ $$2ISSN$$a1058-4838
000274183 0247_ $$2ISSN$$a0162-0886
000274183 0247_ $$2ISSN$$a1537-6591
000274183 0247_ $$2altmetric$$aaltmetric:143418420
000274183 037__ $$aDKFZ-2023-00478
000274183 041__ $$aEnglish
000274183 082__ $$a610
000274183 1001_ $$aMeedt, Elisabeth$$b0
000274183 245__ $$aChronic Active Epstein-Barr Virus Infection controlled by allogeneic stem cell transplantation and EBV-specific T-cells.
000274183 260__ $$aOxford$$bOxford Journals$$c2023
000274183 3367_ $$2DRIVER$$aarticle
000274183 3367_ $$2DataCite$$aOutput Types/Journal article
000274183 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1687350338_6280
000274183 3367_ $$2BibTeX$$aARTICLE
000274183 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000274183 3367_ $$00$$2EndNote$$aJournal Article
000274183 500__ $$a2023 Jun 16;76(12):2200-2202
000274183 520__ $$aWe report sustained remission of chronic active EBV infection in a 27-year-old female patient treated with third-party EBV-specific T-cells followed by allogeneic HSCT. The viremia cleared after administration of anti-T-lymphocyte globulin for GvHD prophylaxis. Subsequent expansion of EBV-infected host T-cells was controlled by transfusion of donor-derived EBV-specific T-cells.
000274183 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000274183 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000274183 650_7 $$2Other$$aCAEBV
000274183 650_7 $$2Other$$aEBV-specific T-cells
000274183 650_7 $$2Other$$aallogeneic stem cell transplantation
000274183 650_7 $$2Other$$aanti-T-lymphocyte globulin
000274183 7001_ $$aWeber, Daniela$$b1
000274183 7001_ $$aBonifacius, Agnes$$b2
000274183 7001_ $$aEiz-Vesper, Britta$$b3
000274183 7001_ $$aMaecker-Kolhoff, Britta$$b4
000274183 7001_ $$0P:(DE-He78)3877ae274d0271d6bf311bb46539f013$$aDelecluse, Susanne$$b5$$udkfz
000274183 7001_ $$0P:(DE-He78)25d3c74b949988c637571e696fc04b25$$aDelecluse, Henri-Jacques$$b6$$udkfz
000274183 7001_ $$aLorenz, Myriam$$b7
000274183 7001_ $$aSchwarz, Klaus$$b8
000274183 7001_ $$aMeedt, Stefan T$$b9
000274183 7001_ $$aBraess, Jan$$b10
000274183 7001_ $$aHerr, Wolfgang$$b11
000274183 7001_ $$aHoller, Ernst$$b12
000274183 7001_ $$aEdinger, Matthias$$b13
000274183 7001_ $$aWolff, Daniel$$b14
000274183 773__ $$0PERI:(DE-600)2002229-3$$a10.1093/cid/ciad131$$gp. ciad131$$n12$$p2200-2202$$tClinical infectious diseases$$v76$$x1058-4838$$y2023
000274183 909CO $$ooai:inrepo02.dkfz.de:274183$$pVDB
000274183 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3877ae274d0271d6bf311bb46539f013$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000274183 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)25d3c74b949988c637571e696fc04b25$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000274183 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000274183 9141_ $$y2023
000274183 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-08
000274183 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-08
000274183 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-08
000274183 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2023-08-24$$wger
000274183 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN INFECT DIS : 2022$$d2023-08-24
000274183 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000274183 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000274183 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-24
000274183 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-24
000274183 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-24
000274183 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
000274183 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-24
000274183 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
000274183 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-24
000274183 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-24
000274183 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bCLIN INFECT DIS : 2022$$d2023-08-24
000274183 9201_ $$0I:(DE-He78)F100-20160331$$kF100$$lF100 Pathologie infektionsbedingter Tumoren$$x0
000274183 980__ $$ajournal
000274183 980__ $$aVDB
000274183 980__ $$aI:(DE-He78)F100-20160331
000274183 980__ $$aUNRESTRICTED